Our CEO Michael Gilman and CBO James Mutamba will be at the 2024 Wells Fargo Healthcare Conference in Boston this week. They’re looking forward to great meetings and connections #ExpeditionRNA
Arrakis Therapeutics
Pharmaceutical Manufacturing
Waltham, MA 10,823 followers
Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients.
Über uns
Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA. We are pioneering new territory, with an expedition led by a team of skilled scientists and drug development leaders who are inventive yet pragmatic. We are on a bold and exciting mission, a mission not without peril, but we have an energized, collaborative, creative and fearless team – a team that has consistently breached barriers and blazed new trails in search of solutions. We are now poised to realize the promise of bringing RNA into play for small-molecule drug discovery. Pushing the frontier of this emerging field of science is gratifying, but our mission goes beyond the thrill of scientific discovery. We believe that by targeting RNA biology in new ways, we have the potential to impact millions of patients. Our platform will allow us to reach hundreds of biological targets not currently accessible to medicine, including known targets previously considered “undruggable.” Our destination is powerful new therapies for patients everywhere, by opening up a new path for discovering RNA-targeted medicines.
- Website
-
http://arrakistx.com
External link for Arrakis Therapeutics
- Industrie
- Pharmaceutical Manufacturing
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Waltham, MA
- Typ
- In Privatbesitz
- Gegründet
- 2015
Standorte
-
Primäre
828 Winter Street
Waltham, MA 02451, US
Employees at Arrakis Therapeutics
-
Katrine Bosley
Founding CEO of DaCapo; Chairman of Arrakis; Venture Partner at Advent Life Sciences. Former CEO of Editas Medicine and of Avila Therapeutics
-
Jakob Loven, PhD
-
Chris O'Donnell
Partner, Pfizer Ventures & Vice President, Partnering Innovations
-
Domi Stickens
Vice President, Head of Discovery and Translational Sciences @ Arrakis Therapeutics | Independent Consultant, Drug Discovery | Private Pilot and…
Aktualisierungen
-
We celebrate and believe in #WomensEquality, recognizing the day in 1920 when women were guaranteed the right to vote. #DareToBeArrakeen
-
At Arrakis, we’re committed to achieving our simple but powerful vision: To extend medicines into new realms of biology by discovering and developing rSMs (RNA-targeted small molecules) that act directly on RNA to treat disease. Happy #RNADay!
-
July is #DisabilityPrideMonth, honoring the anniversary of passage of the Americans with Disabilities Act (ADA) on July 26, 1990. We’re continuing our DEIB Committee program highlighting scientists who have made historic contributions and come from groups under-represented in #STEM, learning about 3 extraordinary scientists with disabilities.
-
The Arrakis team volunteered at Healthy Waltham this week, an organization working to improve the health outcomes of Waltham’s most vulnerable residents. We are constantly inspired by the impactful organizations in our community. #ArrakeensInAction
-
This July 4, we’re thankful to celebrate this holiday that aligns with our value of being human. We’re proud to be based in the state where our independence was born, with such support for life sciences and personal freedoms. #WeAreArrakeen
-
Today, we honor #PrideDay, the international holiday recognizing the first ever celebrations of LGBTQ+ pride. Arrakis gathered for our annual rainbow lunch to celebrate. #WeAreArrakeen
-
CSO Jennifer Petter had a great conversation yesterday with Dawn Thompson from Empress Therapeutics and the other event panelists, with moderator Kyle LaHucik from Endpoints News guiding discussion and Q&A on progress and more work to be done on LGBTQ+ #inclusion in #biotech. #Pride https://lnkd.in/e6Crc7FW
-
This #Pride Month, Jennifer Petter, our Founder and Chief Scientific Officer, joins Endpoints News for a virtual event celebrating the 2024 Endpoints LGBTQ+ Leaders in Biopharma honorees. She was selected in 2022 and will moderate a discussion with a 2024 honoree on their journeys and working for inclusion within companies. https://lnkd.in/e6Crc7FW